NFKB1 and B-cell chronic lymphocytic leukemia: Though CLL cells on ibrutinib have a decreased NFκB binding to DNA elements, activating an alternative NFκB pathway by genetic changes is another mechanism responsible for ibrutinib resistance, mostly in MCL (65).